Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy
- PMID: 17224195
- DOI: 10.1016/j.radonc.2006.12.008
Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy
Abstract
Background: Radiation dose distributions created by two dimensional (2D) treatment planning are responsible for partial volumes receiving >107% of the prescribed dose in a proportion of patients prescribed whole breast radiotherapy after tumour excision of early breast cancer. These may contribute to clinically significant late radiation adverse effects.
Aim: To test three dimensional (3D) intensity modulated radiotherapy (IMRT) against 2D dosimetry using standard wedge compensators in terms of late adverse effects after whole breast radiotherapy.
Methods: Three hundred and six women prescribed whole breast radiotherapy after tumour excision for early stage cancer were randomised to 3D IMRT (test arm) or 2D radiotherapy delivered using standard wedge compensators (control arm). All patients were treated with 6 or 10MV photons to a dose of 50Gy in 25 fractions to 100% in 5 weeks followed by an electron boost to the tumour bed of 11.1Gy in 5 fractions to 100%. The primary endpoint was change in breast appearance scored from serial photographs taken before radiotherapy and at 1, 2 and 5 years follow up. Secondary endpoints included patient self-assessments of breast discomfort, breast hardness, quality of life and physician assessments of breast induration. Analysis was by intention to treat.
Results: 240 (79%) patients with 5-year photographs were available for analysis. Change in breast appearance was identified in 71/122 (58%) allocated standard 2D treatment compared to only 47/118 (40%) patients allocated 3D IMRT. The control arm patients were 1.7 times more likely to have a change in breast appearance than the IMRT arm patients after adjustment for year of photographic assessment (95% confidence interval 1.2-2.5, p=0.008). Significantly fewer patients in the 3D IMRT group developed palpable induration assessed clinically in the centre of the breast, pectoral fold, infra-mammary fold and at the boost site. No significant differences between treatment groups were found in patient reported breast discomfort, breast hardness or quality of life.
Conclusion: This analysis suggests that minimisation of unwanted radiation dose inhomogeneity in the breast reduces late adverse effects. Incidence of change in breast appearance was statistically significantly higher in patients in the standard 2D treatment arm compared with the IMRT arm. A beneficial effect on quality of life remains to be demonstrated.
Similar articles
-
Prospective evaluation of concomitant tumour bed boost with whole breast irradiation in patients with locally advanced breast cancer undergoing breast-conserving therapy.Breast. 2008 Feb;17(1):64-70. doi: 10.1016/j.breast.2007.07.033. Epub 2007 Sep 11. Breast. 2008. PMID: 17851077 Clinical Trial.
-
[Dosimetric evaluation of intensity-modulated tangential beam versus conventional tangential irradiation for breast cancer].Ai Zheng. 2006 Jul;25(7):855-60. Ai Zheng. 2006. PMID: 16831277 Chinese.
-
Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer.Radiother Oncol. 2004 Nov;73(2):133-9. doi: 10.1016/j.radonc.2004.09.013. Radiother Oncol. 2004. PMID: 15542159 Clinical Trial.
-
Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: is there a worthwhile quality of life gain?Cancer Treat Rev. 2011 Nov;37(7):511-9. doi: 10.1016/j.ctrv.2011.01.004. Epub 2011 Feb 15. Cancer Treat Rev. 2011. PMID: 21324605 Review.
-
Techniques of tumour bed boost irradiation in breast conserving therapy: current evidence and suggested guidelines.Acta Oncol. 2007;46(7):879-92. doi: 10.1080/02841860701441798. Acta Oncol. 2007. PMID: 17851869 Review.
Cited by
-
New Approaches in Breast Cancer Radiotherapy.Eur J Breast Health. 2023 Dec 27;20(1):1-7. doi: 10.4274/ejbh.galenos.2023.2023-11-4. eCollection 2024 Jan. Eur J Breast Health. 2023. PMID: 38187103 Free PMC article. Review.
-
Quantitative assessment of breast volume changes after whole-breast irradiation for breast cancer using breast auto-segmentation.Breast Cancer Res Treat. 2024 Jan;203(2):205-214. doi: 10.1007/s10549-023-07146-0. Epub 2023 Oct 13. Breast Cancer Res Treat. 2024. PMID: 37833452
-
Beyond the heart in hypofractionated radiotherapy and in the transition from 3D to IMRT/VMAT.Rep Pract Oncol Radiother. 2023 Aug 28;28(4):478-484. doi: 10.5603/RPOR.a2023.0053. eCollection 2023. Rep Pract Oncol Radiother. 2023. PMID: 37795223 Free PMC article.
-
Cicaderma® in radiation-related dermatitis of breast cancer: Results from the multicentric randomised phase III CICA-RT.Clin Transl Radiat Oncol. 2023 Jun 1;41:100647. doi: 10.1016/j.ctro.2023.100647. eCollection 2023 Jul. Clin Transl Radiat Oncol. 2023. PMID: 37441546 Free PMC article.
-
Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer.ESMO Open. 2023 Jun;8(3):101206. doi: 10.1016/j.esmoop.2023.101206. Epub 2023 May 24. ESMO Open. 2023. PMID: 37236087 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical